- Product: CGuard with MicroNET for Stroke Prevention - Stroke is 2nd Leading Cause of Death Worldwide (WHO) - Currently Sold in 39 Countries - Expanding to Brazil, China, and Japan - CE Mark -- FDA Approval Ongoing - 14 USA, 33 World Patents - 7 Successful Clinical Trials, 4 On-going - Becoming the New Standard of Care - Minimally Invasive Outpatient Procedure - The MicroNET solves the problem of dislodging artery plaque during stent placement - New CEO Marvin Solsman (January 2020) 30yr Exp - GE Healthcare, Cordis, and Integra - Focused on Commercialization and International Market Development - Company Recapitalized for Growth Preparation - 30% Growth in Q42019 - Stroke Management is BIG Business - $34 Billion associated with Stroke Management in USA yearly - Consolidation past few days - Falling wedge - - possible reversal
looking for .5c break and retest of new support PT1 .58c PT2 .79c PT3 .89c PT4 1.04 stop .44c
Comment
⋅
Triple bottom just formed here. Will keep this on watch. Surprised this one hasn't taken off yet.